tirzepatide and dementia reduces food intake appetite, and affects brain functioning, more than placebo and liraglutide Prevention of Dementia with GLP-1

First-time T2D diagnoses within 15 days of the first-time GLP-1 prescription increased with increasing obesity classes between 2020 and 2024 (Class 1: +19.7%, Class 2: +25.9%, Class 3: + 43.7%)

In DCCT, participants were randomised to either intensive or conventional insulin therapy (achieving a median HbA 1c level of 7% vs 9% [53 vs 75 mmol/mol], respectively) and followed for a mean of 6.5 years

Commonly reported side effects include nausea, tiredness, and digestive issues

Using an expired or improperly stored compounded medication is particularly risky because degradation products from peptide breakdown are unpredictable